GAITHERSBURG, Md., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference. Details are as follows:
| Conference: | Guggenheim SMID Cap Biotech Conference |
| Date/Time: | Wednesday, February 5, 2025, at 9:30 a.m. EST |
The session will be webcast and can be accessed by visiting the Events section of the Altimmune website.
About Altimmune
Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH. For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter
Company Contact:
Greg Weaver
Chief Financial Officer
Phone: 240-654-1450
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Contact:
Lee Roth
Burns McClellan
Phone: 646-382-3403
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact:
Danielle Cantey
Inizio Evoke, Biotech
Phone: 619-826-4657
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$4.00 |
| Daily Volume: | 2,287,695 |
| Market Cap: | US$353.040M |
August 19, 2025 August 11, 2025 June 26, 2025 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
